1. Home
  2. UTF vs COGT Comparison

UTF vs COGT Comparison

Compare UTF & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$23.76

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$39.60

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
COGT
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.3B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
UTF
COGT
Price
$23.76
$39.60
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
$28.08
AVG Volume (30 Days)
171.7K
3.5M
Earning Date
01-01-0001
11-03-2025
Dividend Yield
7.19%
N/A
EPS Growth
N/A
N/A
EPS
2.84
N/A
Revenue
$138,636,669.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.16
N/A
Revenue Growth
19.80
N/A
52 Week Low
$22.05
$3.72
52 Week High
$26.53
$43.73

Technical Indicators

Market Signals
Indicator
UTF
COGT
Relative Strength Index (RSI) 45.38 72.28
Support Level $23.47 $37.86
Resistance Level $24.14 $43.73
Average True Range (ATR) 0.26 2.04
MACD -0.04 -0.67
Stochastic Oscillator 28.21 56.31

Price Performance

Historical Comparison
UTF
COGT

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: